Floatz logo

Tcelna

Secondary Progressive Multiple Sclerosis

Opexa Therapeutics, Inc.Cell therapyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

37 Active assets in the Secondary Progressive Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Siponimod
Novartis Pharmaceuticals
Phase 4BBB
Fampridine
University College Dublin
Phase 4BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Cairo University
Phase 3BB
bnt162
Novartis Pharmaceuticals
Phase 4BB
mis416
Innate Immunotherapeutics
Phase 2BB

View all 50 →

Same molecule, other indications

Tcelna is also rated in:

Autoimmune Diseases of the Nervous SystemDormant
B
Indicative ·
57 / 100
View asset →
Disease ProgressionDormant
B
Indicative ·
57 / 100
View asset →
Brain AtrophyDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →